Thromboprophylaxis in pregnancy: Cardiff and Vale’s approach and the reasons why Rachel Rayment, Consultant Haematologist, UHW

Slides:



Advertisements
Similar presentations
Cate Langley MSc Lead Midwife, North Powys. A Survey to identify who, how and what maternity data are collected in Welsh Maternity Units.
Advertisements

Venous Thrombo-embolism In Pregnancy
Implementing NICE guidance
Thromboprophylaxis after delivery
Venous Thromboembolism: Risk Assessment and Prophylaxis
LHD Logo Venous Thromboembolism Reducing the Risk DATE.
STROKE & PREGNANCY By Judith Barnaby, Stroke CNS Reviewed by Dr. Bayer, Stroke Neurologist, St. Michael’s Hospital.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Prophylaxis of Venous Thromboembolism
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Venous Thromboembolism
Deep Vein Thrombosis (DVT)
Beverley Hunt Simon Noble Hospital Acquired Venous Thromboembolism.
Low Molecular Weight Heparin
QAH HospitalPortsmouth Hospitals NHS Trust Venous Thromboembolism Patient Safety Study Day Simon Freathy.
Best Practices in Meeting NPSG 3E-Anticoagulation Requirements MaryAnne Cronin, PharmD Assistant Director of Pharmacy Glen Cove Hospital.
Increasingly, women who are asymptomatic present in pregnancy with a known thrombophilia, typically detected because of screening following identification.
Venous ThromboEmbolism
MANAGEMENT OF THE OBESE PREGNANT PATIENT Max Brinsmead PhD FRANZCOG May 2010.
Venous thromboembolism (VTE) in obstetrics Dr. Yasir Katib MBBS, FRCSC, Perinatologist.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
DVT/VTE Nursing Protocol (Deep Vein Thrombosis) (Venous Thromboembolism) Presented by Maribeth Desiongco MA, RN-BC 2008.
Volume 359: November 6, 2008 Number 19November 6, 2008.
Medical Patients – VTE Prevention Dale W. Bratzler, DO, MPH Professor and Associate Dean, College of Public Health Professor of Medicine, College of Medicine.
Management thrombophilia. introduction Twenty percent of maternal deaths in the United States during that period were attributed to PE. Inherited thrombophilias.
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Thromboprophylaxis in Pregnancy and the Puerperium
Prevention Of Venous Thromboembolism In The Cancer Surgical Patient A K Kakkar Barts and the London School of Medicine and Thrombosis Research Institute,
1 VTE Protocol Presented by: Selina Baskins, RN Quality Coordinator.
TEMPLATE DESIGN © Diet Plus Insulin Compared to Diet Alone In The Treatment of GDM Mothers in HUSM, Kelantan. Wan Faizah.
Venous Thromboembolism
Risk assessment for VTE
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
PERIOPERATIVE MANAGEMENT OF A PARTURIENT WITH PRIOR H/O PULMONARY EMBOLISM AND IVC FILTER IN SITU DR.KRANAPPU SOLOMON,DNB PG DR.RENU DEVAPRASATH,DNB (Anesth)
Preventing Hospital Acquired Thrombosis Simon Noble Peggy Edwards.
VTE Venous ThromboEmbolism. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To define the.
LIFEBLOOD THE Thrombosis CHARITY LIFEBLOOD THE Thrombosis CHARITY NICE Clinical Guideline 46.
VTE Prevention In Action Interactive Case Scenarios.
TEMPLATE DESIGN © Evaluation of the antenatal care and obstetric outcome of obese pregnant women and those with a healthy.
Pregnancy care in women with BMI>35 Dr S Sharma, Dr A Mahmud and Dr N Manheri-OthayothUniversity Hospital of Wales, Cardiff UK Pregnancy care in women.
Venous Thromboembolism Prophylaxis for Medical Inpatients Heather Hofmann, rev. 4/18/14 DSR2 Mini Lecture.
TEMPLATE DESIGN © UNSCHEDULED ADMISSIONS AND DELIVERY IN WOMEN WITH PRIOR CAESAREAN BIRTH AND PLANNED FOR DELIVERY BY.
Risk Assessment for VTE. Which of the following best describes you?
Mandatory Training: VTE prevention and anticoagulation practice Mandatory Training: VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis.
TEMPLATE DESIGN © Audit on Indication for Caesarean Section Basirat Towobola Causeway Hospital, Coleraine, Northern Ireland,
VTE in OBGYN practice DR ANBU SUBBIAN
Diabetes in pregnancy Timing and Mode of Delivery
Postpartum period in women with systemic lupus erythematosus BY DR KH ELMIZADEH.
Venous Thromboembolism (VTE) Prophylaxis at Cesarean Section Phillip N. Rauk, MD.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
ANTENATAL CARE OF DIABETES IN PREGNANCY: AUDIT Rachael Read ST2 O&G Supervisor: Mr E Njiforfut Consultant.
Dr Thomas Lloyd F1 Dr Aman Hargehandewal Wrexham Maelor Hospital
Making Every Contact Count (MECC) and Optimising Outcomes Dr Siân Griffiths Consultant in Public Health Medicine.
Insert name of presentation on Master Slide Hospital Acquired Thrombosis Simon Noble and Mike Fealey.
1 MMM October 2008 AVAIL ME Project Audit of Venous Thromboembolism Management in Middle East Hospitals Elham Mir,MD MPH Medical Affairs Clinical Operation.
Dr. Lesbia Adalgisa Rodriguez PGY3-Cook County Loyola Family Medicine Residency Program Venous Thromboembolism Prophylaxis in the Inpatient Setting.
Outpatient DVT assessment & treatment Daniel Gilada.
Venous Thromboembolism Prophylaxis for Medical Inpatients
Venous Thromboembolism Prophylaxis (VTE)
Transforming Maternity Services Mini-Collaborative
Clinical Knowledge Summaries CKS Pulmonary embolism (PE)
Thromboprophylaxis during labour and delivery
obesITY IN pregnanCY FOR UNDERGRADUATES
1000 lives + Mini Collaborative: Community Bundle
Lessons on Thrombosis and Thromboembolism
GHS Outpatient Enoxaparin Program
Calculate Well’s score for PE (BOX1)
Thrombophilia in pregnancy: Whom to screen, when to treat
Presentation transcript:

Thromboprophylaxis in pregnancy: Cardiff and Vale’s approach and the reasons why Rachel Rayment, Consultant Haematologist, UHW

My remit: Share your DVT risk assessment tool highlighting the change in BMI upper threshhold Explain the knowledge behind and the justification for changes in BMI Implementation of the tool/measures of compliance Clinical feedback to the tool………

…………….In 20 minutes, allowing time for questions………..

The risk assessment tool

Tick if present Previous DVT/PE Refer to haematology clinic Antithrombin deficiency Refer to haematology clinic Systemic lupus erythematosis Refer to haematology clinic Sickle cell disease Refer to haematology clinic Antiphospholipid syndrome Refer to haematology clinic Myeloproliferative disorder Refer to haematology clinic BMI ≥45kg/m 2 Refer to anaesthetic 32/40 if booking BMI ≥ 45 Assessed by Date / Signature Indications to consider antenatal thromboprophylaxis (continue during hospital admission) THROMBOPROPHYLAXIS RISK ASSESSMENT FOR PREGNANT WOMEN Medical staff to assess ALL women at their first hospital antenatal clinic visit

Indications for thromboprophylaxis (TEDS & Clexane) whilst antenatal inpatient (Medical staff to assess at each antenatal admission) Indication One tick = Thromboprophylaxis required Tick if present Hyperemesis Booking BMI ≥35kg/m 2 Dehydration with dry tongue / poor urine output Sepsis Immobility – >3 days bed rest Significant medical co-morbidity (such as heart disease, metabolic, endocrine or respiratory pathologies, acute infectious diseases or inflammatory conditions) Varicose veins with phlebitis Active cancer / cancer treatment Ongoing antenatal thromboprophylaxis Thromboprophylaxis required (Yes/No) Date Signature

Prescription of Thromboprophylaxis: Booking Weight (kg) Enoxaparin dose (mg) frequency <5020od od bd >12060bd

Contraindications to Enoxaparin (CLEXANE) 1. Birth or spinal or epidural analgesia / anaesthesia anticipated within next 12 hours 5. DIC 2. Wait 6 hours following performing spinal or epidural analgesia / anaesthesia or epidural catheter removal 6. Past history of heparin-induced thrombocytopenia (discuss with haematologist) 3. Do not remove epidural catheter within 12 hours of Clexane administration. (If on > 40mg discuss with anaesthetist) 7. Patient is already receiving other anticoagulants (e.g. warfarin/heparin) 3. Active bleeding8. Severe liver disease 4. Platelet count < 75 x 10 9 /l 9. Severe renal impairment: If eGFR < 30ml/min or evidence of acute renal failure use subcutaneous unfractionated heparin 5000u bd Consider below knee antiembolism stockings alone if enoxaparin is contraindicated and thromboprophylaxis needed. Avoid stocking if pedal pulses are impalpable, peripheral vascular disease, severe dermatitis, peripheral neuropathy, recent skin graft

Postnatal Ensure thromboprophylaxis (TEDS & Clexane for 5 days) has been prescribed following birth if one or more factor present Tick if present Women receiving thromboprophylaxis throughout pregnancy should continue treatment for 6 weeks postpartum PPH >1500ml Red blood cell transfusion or transfusion of coagulation factors Caesarean section (elective or emergency) Still-birth BMI >40kg/m 2 Sepsis Complex vaginal delivery (Thromboprophylaxis should be considered) Signature / Date Prescription of Thromboprophylaxis: Booking Weight (kg) Enoxaparin dose (mg) frequencyConsider below knee antiembolism stockings alone if enoxaparin is contraindicated. Avoid stocking if pedal pulses are impalpable, peripheral vascular disease, severe dermatitis, peripheral neuropathy, recent skin graft <5020od od bd >12060bd

CMACE saving mother’s lives Deaths18 BMI >3011 Learning difficulties / mental health disorder 5 Minority ethnic group6 (2 spoke no English) Hyperemesis3 Prolonged immobility2

CEMACE Risk factors – all deaths n=33 BMInumber% > > >35838 >45629 >6025 Weight recorded 25 BMI calculated in 21

Welsh Health Survey % of adults in Wales are overweight or obese 19% of adults in Wales are overweight or obese

Pregnancy associated DVT: Cardiff and Vale 2010 Antenatal: 3 37 weeks in a 21 year old with no risk factors weeks in a 23 year old with no risk factors weeks in a 33 year old with an unplanned pregnancy and a prior history of DVT in pregnancy, not on thromboprophylaxis Up to 6 weeks post-natal: 2 5 days post c/s. 28 year old. Ventilated on ITU, adenocarcinoma in pleural aspirate. Patient died. 28 year old 4 days following SVD of 2nd baby. No complications. No risk factors. >6 weeks <1 year post-natal 24 yr old 8 weeks post partum. Fractured ankle, immobilised with POP, raised BMI 28 year old 5 months post partum. No risk factors

Cardiff and Vale: Pregnancy related PE’s 2010 Antenatal:1 –33 years old. G6P5. BMI <25. –8 weeks gestation, massive PE requiring thrombolysis Post natal:1 –19 year old. No risk factors (BMI <25). –9 weeks post delivery (1 st symptoms 6-7 weeks)

Cardiff and Vale Pregnancy related deaths due to VTE

Thrombosis in pregnancy – the risk factors

Incidence and risk factors for PE in the postpartum period Morris Journal of thrombosis and haemostasis 2010 All deliveries in New South Wales deliveries to women 375 episodes of PE Incidence of PE 0.73/1000 deliveries 7 deaths due to PE Mortality 0.013/1000 (CEMACH 0.015/1000)

Pregnancy/delivery factorAdjuste d OR 95% CI SLE Transfusion of coagulation factors – 17.3 Stillbirth in current pregnancy VTE in a prior birth * Red Cell transfusion *1 case in 260 PE’s had a history of VTE in previous birth

Pregnancy/delivery factorAdjusted OR 95% CI Caesarean section during labour Caesarean section without labour 3.11* Preterm live-birth (<37 weeks) Pregnancy hypertension *No significant difference between c/s during labour and without labour

Pregnancy/delivery factorAdjusted OR 95% CI Parity > LGA (10 th percentile) SGA (<10 th percentile) Smoker

What is the evidence in favour of thromboprophylaxis in pregnancy?

Cochrane review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period Tooher, Cochrane Database 2010 issue 5

13 trials 1774 women 4 trials: antenatal thromboprophylaxis –UFH vs LMWH ( 2 studies) –heparin vs no treatment (2 studies) 8 trials: thromboprophylaxis post c/s –HES v UFH (1 study) –Heparin vs placebo (4 studies) –UFH vs LMWH (3 studies) 1 trial post-natal thromboprophylaxis

Cochrane review conclusion “There is insufficient evidence from RCTs to guide clinical decision making” “Practionners must rely on consensus derived clinical practice guidelines”

Risk scoring in pregnancy Dargaud BJHaem 2009 Prospective multicentre clinical trial women Personal h/o VTE or Known thrombophilia

ScoreAntenatal TPPostnatal TP <3NoYes 3-53 rd trimesterYes >6>6 Clinical management according to risk score

Clinical outcomes according to risk score

Consider offering LMWH if pregnant woman is admitted and: Expected to be immobile for >3 days Known thrombophilia >35 yearsPersonal history VTE Critical care admission!st degree relative with VTE DehydrationHyperemesis gravidarum Excess blood loss or blood transfusion BMI >30kg/m 2 OHSSPre-Eclampsia Multiple pregnancyVaricose veins with phlebitis NICE guidance- 92, 2010

Additional Risk Factors for VTE Thromboprophylaxis following caesarean section? ACCP (grade)NICERCOG (grade) NoneNo (1B)Emergency c/s: 7 days LMWH Emergency c/s: 7 days LMWH (C) > 1 LMWH OR Mechanical Method for duration of hospital stay (2 C) Elective c/s: 7 days LMWH ALL: 7 days LMWH if BMI >40kg/m 2 Elective c/s: 7 days LMWH (C) ALL: 7 days LMWH if BMI >40kg/m 2 (C) Multiple – at very high risk LMWH AND Mechanical Method for duration of hospital stay (2C) Selected patients with persisting risk Extended thromboprophylaxis following discharge (up to 6 weeks) (2C)

Post natal thromboprophylaxis RCOGSIGN >2 persisting risk factorsLMWH for 7 days (C) >3persisting risk factorsAES + LMWH for 7 days (C) BMI >40kg/mLMWH for 7 days (consensus) YES (C) Emergency section (category 1,2 or 3) LMWH for 7 days (C)YES (C) Elective caesarean section + 1 risk factor LMWH for 7 days (C)YES (C) asymptomatic heritable or acquired thrombophilia LMWH at 7 days – 6 weeks (C) YES (C) Women with previous VTELMWH until 6 weeks (C)YES (C) Women receiving LMWH antenatallyLMWH until 6 weeks (C)YES (C) In women who have additional persistent risk factors thromboprophylaxis LMWH up to 6 weeks (consensus)

RCOG guidance: Green top guideline 37 (2009) Antenatal management: The major change

Antenatal Thromboprophylaxis with LMWH should be considered if: ≥ 3 risk factors and managed as an outpatient ≥ 2 risk factors and managed as an inpatient a Score 1 for BMI > 30 kg/m2; 2 for BMI > 40 kg/m2 (BMI based on booking weight)

Risk scoring at time of delivery – added to pre-existing factors. ≥ 2 risk factors give LMWH for 7 days

Pregnancy/delivery factorAdjusted OR95% CI Previous VTE (all) SLE Obstetric haemorrhage Transfusion (all) Stillbirth in current pregnancyNot recorded Caesarean section during labour Caesarean section without labour Preterm live-birth (<37 weeks) Pregnancy hypertension Parity > Weight >120kg kg RCOG – the stats behind the recommendations